Evidence map›Paper›PMID 36597067›Full record

ArticleJournal of nanobiotechnology2023

Dual-stimuli responsive smart nanoprobe for precise diagnosis and synergistic multi-modalities therapy of superficial squamous cell carcinoma.

Peisen Zhang, Yingying Cui, Jian Wang, Junwei Cheng, Lichong Zhu, Chuang Liu, Saisai Yue, Runxin Pang, Jiaoqiong Guan, Bixia Xie and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Peisen Zhang *Department of Rehabilitation Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 510180, Guangzhou, China.
Yingying Cui *College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Jian Wang *Department of Head and Neck Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, China.
Junwei ChengCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Lichong ZhuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Chuang LiuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Saisai YueCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Runxin PangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Jiaoqiong GuanDepartment of Rehabilitation Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 510180, Guangzhou, China.
Bixia XieCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Ni ZhangDepartment of Psychiatry, West China Hospital, National Chengdu Center for Safety Evaluation of Drugs, Sichuan University, Chengdu, 610041, China.
Meng QinCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Lihong JingKey Laboratory of Colloid, Interface and Chemical Thermodynamics, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.
Yi HouCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 10029, China.
Yue LanDepartment of Rehabilitation Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 510180, Guangzhou, China. bluemooning@163.com.
Beijing University of Chemical Technology · CNChinese Academy of Sciences · CNGuangzhou First People's Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNInstitute of Chemistry · CNSouth China University of Technology · CN

Funding

Central Universities of China buctrc201934National Natural Science Foundation of China 22177115National Natural Science Foundation of China 52003021National Natural Science Foundation of China 81772438National Natural Science Foundation of China 82102679Postdoctoral Science Foundation of China 2021M700931
6 · The paper itself

Abstract

backgroundAlthough the promising advancements of current therapeutic approaches is available for the squamous cell carcinoma (SCC) patients, the clinical treatment of SCC still faces many difficulties. The surgical irreparable disfigurement and the postoperative wound infection largely hamper the recovery, and the chemo/radiotherapy leads to toxic side effects.

resultsHerein, a novel pH/Hyaluronidase (HAase) dual-stimuli triggered smart nanoprobe Fe

conclusionThe current Fe

Indexed as

Carcinoma, Squamous CellNanoparticlesNeoplasmsCD8-Positive T-LymphocytesCell Line, TumorHumansPhototherapyTumor MicroenvironmentDual-stimuli responsive nanoprobePrecise diagnosisSquamous cell carcinomaSynergistic therapy

Identifiers

PMID36597067
PMCPMC9808965
OpenAlexW4313522493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.